MTOR and nonpapillary renal cell carcinoma: Over the past two decades, various therapeutic approaches have emerged for advanced ccRCC, including immune therapies or molecularly targeted therapies that focus on particularly targeting receptor tyrosine kinase (RTK) or mammalian rapamycin (mTOR) [3].